[Angioedema caused by C1 esterase inhibitor deficiency].
Jentsch-Ullrich
K
K
Klinik für Hämatologie/Onkologie, Zentrum für Innere Medizin, Otto-von-Guericke-Universität Magdeburg.
Leuner
S
S
Kahl
C
C
Arland
M
M
Florschütz
A
A
Franke
A
A
Höffkes
H G
HG
D045930:Anabolic Agents / Q000627:therapeutic use; D000799:Angioedema / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D003174:Complement C1 Inactivator Proteins / Q000172:deficiency* / Q000502:physiology / Q000627:therapeutic use; D003613:Danazol / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010956:Plasmapheresis; D013197:Stanozolol / Q000627:therapeutic use
D045930:Anabolic Agents; D000933:Antifibrinolytic Agents; D003174:Complement C1 Inactivator Proteins; D004965:Estrogen Antagonists; D007166:Immunosuppressive Agents; D013197:Stanozolol; D003613:Danazol
Angioödeme durch C1-Esterase-Inhibitor-Mangel.